VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Income Statement
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.10B | 11.02B | 9.87B | 8.93B | 7.57B | |||
| Minority Interest Expense | N/A | N/A | N/A | N/A | N/A | |||
| Cost Of Goods | 1.55B | 1.53B | 1.26B | 1.08B | 904.20M | |||
| Gross Profit | 9.55B | 9.49B | 8.61B | 7.85B | 6.67B | |||
| Operating Expenses | 5.34B | 5.09B | 4.25B | 3.53B | 3.89B | |||
| Research and Development | 3.82B | 3.63B | 3.16B | 2.64B | 3.05B | |||
| Selling, General, and Administrative Expenses | 1.52B | 1.46B | 1.14B | 944.70M | 840.10M | |||
| Operating Income | 4.21B | 4.40B | 4.36B | 4.32B | 2.78B | |||
| Interest Income/Expense | 492.80M | 558.00M | 563.10M | -59.30M | -39.50M | |||
| Other Income/Expense | -50.70M | -76.60M | -15.30M | -15.70M | -12.20M | |||
| Non Recurring Items | -4.95B | -4.63B | -527.10M | -13.00M | 3.10M | |||
| Income Before Taxes | -300.20M | 248.50M | 4.38B | 4.23B | 2.73B | |||
| Income Tax | 688.70M | 784.10M | 760.20M | 910.40M | 388.30M | |||
| Net Income | -988.90M | -535.60M | 3.62B | 3.32B | 2.34B | |||
| EBITDA | 4.41B | 4.60B | 4.54B | 4.47B | 2.91B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.88 | -2.08 | 13.89 | 12.82 | 9.01 | |||
| Non GAAP EPS | -0.41 | 0.29 | 15.22 | 14.89 | 13.02 | |||
| Statistics | ||||||||
| Gross Profit Margin | 86.03% | 86.11% | 87.21% | 87.90% | 88.06% | |||
| Profit Margin | -8.91% | -4.86% | 36.68% | 37.20% | 30.92% | |||
| Operating Profit Margin | 37.91% | 39.89% | 44.17% | 48.38% | 36.73% | |||
All data in USD